The Biosimilar Forum Recognizes Leah Christl’s Departure from FDA
Washington, D.C. February 1, 2018 – The Biosimilars Forum today recognized the announced departure of Leah Christl from the FDA with the following statement:"The Biosimilars Forum has great respect and appreciation for Leah Christl’s work at the FDA and contributions to help create this new industry and department in the Agency. Leah was and will continue to be an excellent leader and partner within the biosimilars industry."
"The Forum looks forward to building on her legacy and working with Sarah Yim to continue to strengthen the biosimilars program, improve guidelines to combat misinformation and optimize approval processes. All of these areas will help unlock the billions in healthcare savings that biosimilars can offer and improve patient access."